FDA asks for more Zevalin info

The FDA is seeking more information on Spectrum Pharmaceuticals' cancer drug Zevalin. And that news cut into the company's share price, which dropped 15 percent. Spectrum swiftly countered by announcing that it will respond to the FDA's complete response letter by Wednesday, but added that the agency's request will delay any approval by two months. Zevalin was originally approved in 2001" but never lived up to expectations. Spectrum is now seeking approval to use the therapy as a first-line treatment for patients with non-Hodgkin's lymphoma. "This is clearly not the result we were looking for, but we're still very confident about [Zevalin's] approval," Spectrum spokesman Paul Arndt told TheStreet Sunday night. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.